Nurix Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRIX research report →
Range $28 – $45
Price Chart
About the company
Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
- CEO
- Arthur T. Sands
- IPO
- 2020
- Employees
- 317
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on NRIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.81B
- P/E
- -7.84
- PEG
- 0.30
- P/S
- 76.36
- P/B
- 7.46
- EV/EBITDA
- -8.75
- Div Yield
- 0.00%
- Gross Margin
- -165.51%
- Op Margin
- -982.37%
- Net Margin
- -928.44%
- ROE
- -76.09%
- ROIC
- -77.32%
Latest fiscal year · YoY change
- Revenue
- $83.98M+54.0%
- Gross Profit
- $65.12M+139.0%
- Op Income
- $-285,666,000
- Net Income
- $-264,457,000-36.6%
- EPS
- $-3.05-5.9%
- OCF Growth
- -44.5%
- FCF Growth
- -44.9%
- 52W High
- $28.23
- 52W Low
- $8.20
- 50D MA
- $22.83
- 200D MA
- $18.08
- Beta
- 1.79
- RSI (14)
- 67
- Avg Volume
- 2.03M
No earnings-call transcripts are available for NRIX yet.
- Free Float
- 94.7%
- Shares Outstanding
- 103.78M
- Float Shares
- 98.26M
of shares held by institutions
198 13F filers
Buy/sell ratio 0.57. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.77M | ▼ 155.29K |
| Vestal Point Capital, LP | 8.05M | ▲ 1.55M |
| Deep Track Capital, LP | 7.74M | ▲ 1.39M |
| Rubric Capital Management LP | 7.23M | ▲ 4.75M |
| Vanguard Group Inc | 5.95M | ▲ 1.46M |
| Fmr LLC | 5.49M | ▼ 56.06K |
| Price T Rowe Associates Inc | 5.44M | ▲ 2.15M |
| Morgan Stanley | 4.76M | ▼ 169.51K |
| State Street Corp | 4.68M | ▼ 463.95K |
| Baker Bros. Advisors LP | 4.66M | 0 |
| Vanguard Capital Management LLC | 4.50M | ▲ 68.42K |
| Perceptive Advisors LLC | 4.32M | ▲ 609.54K |
Held by 208 ETFs
Biggest fund positions in NRIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 26 | Hansen Gwenn | other | 4,356 |
| Aug 5, 26 | Hansen Gwenn | sell | 4,356 |
| Aug 5, 26 | Hansen Gwenn | other | 4,356 |
| Aug 4, 26 | Hansen Gwenn | sell | 1,500 |
| Aug 4, 26 | Hansen Gwenn | sell | 2,611 |
| Aug 4, 26 | van Houte Hans | sell | 1,794 |
| Aug 4, 26 | van Houte Hans | sell | 2,967 |
| Aug 3, 26 | Ring Christine | other | 5,787 |
| Aug 3, 26 | Ring Christine | other | 5,787 |
| Aug 3, 26 | Ring Christine | sell | 16,589 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRIX coverage
Recent articles, reports, and earnings notes.
No research on NRIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRIX report →Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
globenewswire.com · Aug 20
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
defenseworld.net · Aug 11
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
globenewswire.com · Aug 4
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
globenewswire.com · Aug 4
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
zacks.com · Jul 23
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com · Jul 21
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX
defenseworld.net · Jul 21
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
zacks.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.